Ibrutinib, a BTK inhibitor developed to treat chronic lymphocytic leukemia and small lymphocytic lymphoma, has shown promise in treating aggressive glioblastoma by interacting with BMX. Here, BMX is linked to B-cell chronic lymphocytic leukemia.